Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

At the 2017 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), the International Dermatology Outcome Measures (IDEOM) psoriasis working group presented an overview of its cutaneous domain of psoriatic arthritis (PsA) projects. First, the group presented an overview of IDEOM's work to establish psoriasis outcome measures that satisfy the needs of all those involved. Second, the group discussed replacements for the Psoriasis Area and Severity Index (PASI) that can be used in clinical practice, including data that support the use of the physician's global assessment × body surface area measurement score as a PASI surrogate. Third, the group discussed the contribution of skin disease to composite measures of PsA. Last, the group summarized the National Psoriasis Foundation's efforts to establish treat-to-target strategies for psoriasis care.

Original publication

DOI

10.3899/jrheum.180137

Type

Journal article

Journal

J rheumatol suppl

Publication Date

06/2018

Volume

94

Pages

40 - 43

Keywords

GRAPPA, IDEOM, MINIMAL DISEASE ACTIVITY, PSORIASIS, PSORIASIS OUTCOMES, PSORIATIC ARTHRITIS, Arthritis, Psoriatic, Dermatology, Humans, Outcome Assessment (Health Care), Psoriasis, Rheumatology, Severity of Illness Index, Skin